Pharmacological Inhibition of Protein Tyrosine Phosphatase 1B: A Promising Strategy for the Treatment of Obesity and Type 2 Diabetes Mellitus

Current Medicinal Chemistry

Volumn 20, Issue 21, 2013, Pages 2609-2625

  Panzhinskiy, E ^a   Ren, J ^a   Nair, S ^a  

^a UNIVERSITY OF WYOMING COLLEGE OF HEALTH SCIENCES   (United States)

Author keywords

Cell signaling; ER stress; Insulin resistance; Insulin signaling; Leptin signaling; Obesity; PTP1B; PTP1B inhibitors; Type 2 diabetes.

Indexed keywords

DAMMARAN; ERTIPROTAFIB; GLUCOSE; GLYCYRRHIZA URALENSIS EXTRACT; HERBACEOUS AGENT; INSULIN; ISOFLAVONOID; LAMELLODYSEDIA HERBACEA EXTRACT; LEPTIN; LICOCHALCONE A; MORUS BOMBYCIS EXTRACT; PAEONIA LACTIFLORA EXTRACT; PLANT EXTRACT; PRODRUG; PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR; RHODODENDRIC ACID A; SAPOGENIN; TRITERPENE DERIVATIVE; TRODUSQUEMINE; UNCLASSIFIED DRUG; URSOLIC ACID;

ALLOSTERISM; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTIDIABETIC ACTIVITY; ARTICLE; BINDING AFFINITY; DRUG BIOAVAILABILITY; DRUG PENETRATION; DRUG SCREENING; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG SYNTHESIS; DRUG TARGETING; ENDOCRINE DISEASE; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVE SITE; ENZYME CONFORMATION; ENZYME INHIBITION; ENZYME STRUCTURE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; IC 50; INSULIN SENSITIVITY; MEMBRANE PERMEABILITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-OBESITY AGENTS; ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; OBESITY; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84880288048     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320210001     Document Type: Article

References (146)

1. Ahima, R.S. Digging deeper into obesity. J. Clin. Invest., 2011, 121(6), 2076-2079.
2. Hotamisligil, G.S. Inflammation and metabolic disorders. Nature, 2006, 444 (7121), 860-867.
3. Orgel, E.; Mittelman, S. The links between insulin resistance, diabetes, and cancer. Curr. Diab. Rep., 2013, 13(2) 213-222.
4. Ramachandrappa, S.; Farooqi, I.S. Genetic approaches to understanding human obesity. J. Clin. Invest., 2011, 121(6), 2080-2086.
5. World Health Organization. Obesity and overweight fact sheet. http://www.who.int/mediacentre/factsheets/fs311/en/index.html (Accessed February 16, 2013).
6. Ogden, C.L.; Caroll, M.D; Kit, B.K.; Flegal, K.M. Prevalence of obesity in the United States, 2009-2010; NCHS data brief, no 82, January 2012. http://www.cdc.gov/nchs/data/databriefs/db82.pdf (Accessed February 17, 2013).
7. Centers for Disease Control and Prevention. Overweight and obesity. Adult obesity facts. http://www.cdc.gov/obesity/data/adult.html (Accessed February 16, 2013).
8. Weiss, R.; Bremer, A.A.; Lustig, R.H. What is metabolic syndrome, and why are children getting it? Ann. N. Y. Acad. Sci. 2013. 1281(1), 123-140.
9. Centers for Disease Control and Prevention. Overweight and Obesity. Childhood Obesity Facts. http://www.cdc.gov/obesity/data/childhood.html (Accessed February 16, 2013).
10. Verbeeten, K.C.; Elks, C.E.; Daneman, D.; Ong, K.K. Association between childhood obesity and subsequent type 1 diabetes: A systematic review and meta-analysis. Diabet. Med., 2011, 28(1), 10-18.
11. Bahrami, H.; Bluemke, D.A.; Kronmal, R.; Bertoni, A.G.; Lloyd-Jones, D.M.; Shahar, E.; Szklo, M.; Lima, J.A.C. Novel metabolic risk factors for incident heart failure and their relationship with obesity: The MESA (multi-ethnic study of atherosclerosis) study. J. Am. Coll. Cardiol., 2008, 51(18), 1775-1783.
12. Van Gaal, L.F.; Mertens, I.L.; De Block, C.E. Mechanisms linking obesity with cardiovascular disease. Nature, 2006, 444 (7121), 875-880.
13. Elangbam, C.S. Review paper: Current strategies in the development of anti-obesity drugs and their safety concerns. Vet. Pathol. Online, 2009, 46 (1), 10-24.
14. Hussain, A.; Claussen, B.; Ramachandran, A.; Williams, R. Prevention of type 2 diabetes: A review. Diabetes Res. Clin. Pract., 2007, 76 (3), 317-326.
15. Ioannides-Demos, L.L.; Piccenna, L.; McNeil, J.J., Pharmacotherapies for obesity: Past, current, and future therapies. J. Obes., 2011, 2011, 1-18.
16. Despres, J.P.; Lemieux, I. Abdominal obesity and metabolic syndrome. Nature, 2006, 444 (7121), 881-887.
17. Shoelson, S.E.; Lee, J.; Goldfine, A.B. Inflammation and insulin resistance. J. Clin. Invest., 2006, 116 (7), 1793-1801.
18. Tsatsoulis, A.; Mantzaris, M.D.; Bellou, S.; Andrikoula, M. Insulin resistance: An adaptive mechanism becomes maladaptive in the current environment-an evolutionary perspective. Metabolism, 2012, 62(5), 622-633.
19. Mehran, A.E.; Templeman, N.M.; Brigidi, G.S.; Lim, G.E.; Chu, K.-Y.; Hu, X.; Botezelli, J.D.; Asadi, A.; Hoffman, B.G.; Kieffer, T.J.; Bamji, S.X.; Clee, S.M.; Johnson, J.D. Hyperinsulinemia drives diet-induced obesity independently of brain insulin production. Cell Metab., 2012, 16 (6), 723-737.
20. Kahn, S.E.; Hull, R.L.; Utzschneider, K.M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature, 2006, 444 (7121), 840-846.
21. Hotamisligil, G.S. Inflammation and endoplasmic reticulum stress in obesity and diabetes. Int. J. Obes. (Lond), 2008, 32 (S7), S52-S54.
22. Romeo, G.R.; Lee, J.; Shoelson, S.E. Metabolic syndrome, insulin resistance, and roles of inflammation-mechanisms and therapeutic targets. Arterioscler. Thromb. Vasc. Biol., 2012, 32 (8), 1771-1776.
23. Beale, E.G. Insulin signaling and insulin resistance. J. Investig. Med., 2013, 61 (1), 11-14.
24. Hussain, A.; Hydrie, M.Z.I.; Claussen, B.; Asghar, S. Type 2 diabetes and obesity: A review. J. Diabetology, 2010, 2(1), 1-7.
25. Yamauchi, T.; Kadowaki, T. Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab., 2013, 17(2), 185-196.
26. Lavallard, V.J.; Meijer, A.J.; Codogno, P.; Gual, P. Autophagy, signaling and obesity. Pharmacol. Res., 2012, 66 (6), 513-525.
27. Caldwell, S.H.; Argo, C.K.; Al-Osaimi, A.M.S., Therapy of NAFLD: Insulin sensitizing agents. J. Clin. Gastroenterol., 2006, 40, S61-S66.
28. Cheon, H. Latest research and development trends in non-insulin anti-diabetics. Arch. Pharm. Res., 2013, 26(2), 145-153.
29. Zhang, Z.-Y.; Lee, S.-Y. PTP1B inhibitors as potential therapeutics in the treatment of Type 2 diabetes and obesity. Expert Opin. Inv. Drug., 2003, 12 (2), 223-233.
30. Gautron, L.; Elmquist, J.K. Sixteen years and counting: An update on leptin in energy balance. J. Clin. Invest., 2011, 121(6), 2087-2093.
31. Forsell, P.A.L.; Boie, Y.; Montalibet, J.; Collins, S.; Kennedy, B.P. Genomic characterization of the human and mouse protein tyrosine phosphatase-1B genes. Gene, 2000, 260(1-2), 145-153.
32. Lee, S.; Wang, Q. Recent development of small molecular specific inhibitor of protein tyrosine phosphatase 1B. Med. Res. Rev., 2007, 27(4), 553-573.
33. Thareja, S.; Aggarwal, S.; Bhardwaj, T.R.; Kumar, M. Protein tyrosine phosphatase 1B inhibitors: A molecular level legitimate approach for the management of diabetes Mellitus. Med. Res. Rev., 2012, 32(3), 459-517.
34. Popov, D. Novel protein tyrosine phosphatase 1B inhibitors: Interaction requirements for improved intracellular efficacy in type 2 diabetes mellitus and obesity control. Biochem. Biophys. Res. Commun., 2011, 410 (3), 377-381.
35. Sreejayan, N.; Lin, Y.; Hassid, A. NO attenuates insulin signaling and motility in aortic smooth muscle cells via protein tyrosine phosphatase 1B-mediated mechanism. Arterioscler. Thromb. Vasc. Biol., 2002, 22(7), 1086-1092.
36. Shimizu, S.; Ugi, S.; Maegawa, H.; Egawa, K.; Nishio, Y.; Yoshizaki, T.; Shi, K.; Nagai, Y.; Morino, K.; Nemoto, K.-i.; Nakamura, T.; Bryer-Ash, M.; Kashiwagi, A. Protein-tyrosine phosphatase 1B as new activator for hepatic lipogenesis via sterol regulatory element-binding protein-1 gene expression. J. Biol. Chem., 2003, 278(44), 43095-43101.
37. Wang, J.-F.; Gong, K.; Wei, D.-Q.; Li, Y.-X.; Chou, K.-C. Molecular dynamics studies on the interactions of PTP1B with inhibitors: From the first phosphate-binding site to the second one. Protein Eng., Des. Sel., 2009, 22(6), 349-355.
38. Combs, A.P. Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer. J. Med. Chem., 2009, 53(6), 2333-2344.
39. Brandão, T.A.S.; Hengge, A.C.; Johnson, S.J. Insights into the reaction of protein-tyrosine phosphatase 1B: Crystal structures for transition state analogs of both catalytic steps. J. Biol. Chem., 2010, 285(21), 15874-15883.
40. Özcan, A.; Olmez, E.O.; Alakent, B. Effects of protonation state of Asp181 and position of active site water molecules on the confor mation of PTP1B. Proteins: Structure, Function, and Bioinformatics, 2013, 81(5), 788-804.
41. Brandão, T.A.S.; Johnson, S.J.; Hengge, A.C. The molecular details of WPD-loop movement differ in the protein-tyrosine phosphatases YopH and PTP1B. Arch. Biochem. Biophys., 2012, 525(1), 53-59.
42. Bishop, A.C.; Blair, E.R. A gatekeeper residue for inhibitor sensitization of protein tyrosine phosphatases. Bioorg. Med. Chem. Lett., 2006, 16(15), 4002-4006.
43. Puius, Y.A.; Zhao, Y.; Sullivan, M.; Lawrence, D.S.; Almo, S.C.; Zhang, Z.-Y. Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: A paradigm for inhibitor design. Proc. Natl. Acad. Sci. U. S. A., 1997, 94(25), 13420-13425.
44. Wiesmann, C.; Barr, K.J.; Kung, J.; Zhu, J.; Erlanson, D.A.; Shen, W.; Fahr, B.J.; Zhong, M.; Taylor, L.; Randal, M.; McDowell, R.S.; Hansen, S.K. Allosteric inhibition of protein tyrosine phosphatase 1B. Nat. Struct. Mol. Biol., 2004, 11(8), 730-737.
45. Olmez, E.O.; Alakent, B. Alpha7 helix plays an important role in the conformational stability of PTP1B. J. Biomol. Struct. Dyn., 2011, 28(5), 675-693.
46. Zabolotny, J.M.; Bence-Hanulec, K.K.; Stricker-Krongrad, A.; Haj, F.; Wang, Y.; Minokoshi, Y.; Kim, Y.-B.; Elmquist, J.K.; Tartaglia, L.A.; Kahn, B.B.; Neel, B.G. PTP1B regulates leptin signal transduction in vivo. Dev. Cell, 2002, 2(4), 489-495.
47. Yip, S.-C.; Saha, S.; Chernoff, J. PTP1B: A double agent in metabolism and oncogenesis. Trends Biochem. Sci., 2010, 35(8), 442-449.
48. Stuible, M.; Tremblay, M.L. In control at the ER: PTP1B and the down-regulation of RTKs by dephosphorylation and endocytosis. Trends Cell Biol., 2010, 20(11), 672-679.
49. Klaman, L.D.; Boss, O.; Peroni, O.D.; Kim, J.K.; Martino, J.L.; Zabolotny, J.M.; Moghal, N.; Lubkin, M.; Kim, Y.-B.; Sharpe, A.H.; Stricker-Krongrad, A.; Shulman, G.I.; Neel, B.G.; Kahn, B.B. Increased energy expenditure, decreased adiposity, and tissuespecific insulin sensitivity in protein-tyrosine phosphatase 1Bdeficient mice. Mol. Cell. Biol., 2000, 20(15), 5479-5489.
50. Elchebly, M.; Payette, P.; Michaliszyn, E.; Cromlish, W.; Collins, S.; Loy, A.L.; Normandin, D.; Cheng, A.; Himms-Hagen, J.; Chan, C.-C.; Ramachandran, C.; Gresser, M.J.; Tremblay, M.L.; Kennedy, B.P. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science, 1999, 283(5407), 1544-1548.
51. Xue, B.; Pulinilkunnil, T.; Murano, I.; Bence, K.K.; He, H.; Minokoshi, Y.; Asakura, K.; Lee, A.; Haj, F.; Furukawa, N.; Catalano, K.J.; Delibegovic, M.; Balschi, J.A.; Cinti, S.; Neel, B.G.; Kahn, B.B. Neuronal protein tyrosine phosphatase 1B deficiency results in inhibition of hypothalamic AMPK and isoform-specific activation of AMPK in peripheral tissues. Mol. Cell. Biol., 2009, 29(16), 4563-4573.
52. Banno, R.; Zimmer, D.; De Jonghe, B.C.; Atienza, M.; Rak, K.; Yang, W.; Bence, K.K. PTP1B and SHP2 in POMC neurons reciprocally regulate energy balance in mice. J. Clin. Invest., 2010, 120(3), 720-734.
53. Bence, K.K.; Delibegovic, M.; Xue, B.; Gorgun, C.Z.; Hotamisligil, G.S.; Neel, B.G.; Kahn, B.B. Neuronal PTP1B regulates body weight, adiposity and leptin action. Nat. Med., 2006, 12(8), 917-924.
54. Pauli, J.; Ropelle, E.R.; Cintra, D.E.; De Souza, C.T.; da Silva, A.S.R.; Moraes, J.C.; Prada, P.O.; de Almeida Leme, J.A.C.; Luciano, E.; Velloso, L.A.; Carvalheira, J.B.C.; Saad, M.J.A. Acute exercise reverses aged-induced impairments in insulin signaling in rodent skeletal muscle. Mech. Ageing Dev., 2010, 131(5), 323-329.
55. Gonzalez-Rodriguez, A.; Gutierrez, J.A.M.; Sanz-Gonzalez, S.; Ros, M.; Burks, D.J.; Valverde, A.M. Inhibition of PTP1B restores IRS1-mediated hepatic insulin signaling in IRS2-deficient mice. Diabetes, 2010, 59(3), 588-599.
56. Zabolotny, J.M.; Kim, Y.-B.; Welsh, L.A.; Kershaw, E.E.; Neel, B.G.; Kahn, B.B. Protein-tyrosine phosphatase 1B expression is induced by inflammation in vivo. J. Biol. Chem., 2008, 283(21), 14230-14241.
57. Sun, C.; Zhang, F.; Ge, X.; Yan, T.; Chen, X.; Shi, X.; Zhai, Q. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab., 2007, 6(4), 307-319.
58. Ali, M.I.; Ketsawatsomkron, P.; Belin de Chantemele, E.J.; Mintz, J.D.; Muta, K.; Salet, C.; Black, S.M.; Tremblay, M.L.; Fulton, D.J.; Marrero, M.B.; Stepp, D.W. Deletion of protein tyrosine phosphatase 1b improves peripheral insulin resistance and vascular function in obese, leptin-resistant mice via reduced oxidant tone. Circ. Res., 2009, 105(10), 1013-1022.
59. Zhao, M.; Zhang, Z.F.; Ding, Y.; Wang, J.B.; Li, Y. Astragalus polysaccharide improves palmitate-induced insulin resistance by inhibiting PTP1B and NF-kappaB in C2C12 myotubes. Molecules, 2012, 17(6), 7083-7092.
60. Popov, D. Endoplasmic reticulum stress and the on site function of resident PTP1B. Biochem. Biophys. Res. Commun., 2012, 422(4), 535-538.
61. Fu, S.; Yang, L.; Li, P.; Hofmann, O.; Dicker, L.; Hide, W.; Lin, X.; Watkins, S.M.; Ivanov, A.R.; Hotamisligil, G.S. Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity. Nature, 2011, 473(7348), 528-531.
62. Fu, S.; Watkins, S.M.; Hotamisligil, G.S. The role of endoplasmic reticulum in hepatic lipid homeostasis and stress signaling. Cell Metab., 2012, 15(5), 623-634.
63. Pagliassotti, M.J. Endoplasmic reticulum stress in nonalcoholic fatty liver disease. Annu. Rev. Nutr., 2012, 32(1), 17-33.
64. Hotamisligil, G.S. Role of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in inflammation and origin of obesity and diabetes. Diabetes, 2005, 54(S2), S73-S78.
65. Zha, B.S.; Zhou, H. ER stress and lipid metabolism in adipocytes. Biochem Research International [Online], 2012. http://www.hindawi.com/journals/bcri/ 2012/312943/cta/(Accessed February 16, 2013).
66. Back, S.H.; Kaufman, R.J. Endoplasmic reticulum stress and type 2 diabetes. Annu. Rev. Biochem., 2012, 81(1), 767-793.
67. Delibegovic, M.; Zimmer, D.; Kauffman, C.; Rak, K.; Hong, E.-G.; Cho, Y.-R.; Kim, J.K.; Kahn, B.B.; Neel, B.G.; Bence, K.K. Liverspecific deletion of protein-tyrosine phosphatase 1B (PTP1B) improves metabolic syndrome and attenuates diet-induced endoplasmic reticulum stress. Diabetes, 2009, 58(3), 590-599.
68. Agouni, A.; Mody, N.; Owen, C.; Czopek, A.; Zimmer, D.; Bentires-Alj, M.; Bence, K.K.; Delibegovic, M. Liver-specific deletion of protein tyrosine phosphatase (PTP) 1B improves obesity-and pharmacologically induced endoplasmic reticulum stress. Biochem. J., 2011, 438(2), 369-378.
69. Gu, F.; Nguyên, D.T.; Stuible, M.; Dubé, N.; Tremblay, M.L.; Chevet, E. Protein-tyrosine phosphatase 1B potentiates IRE1 signaling during endoplasmic reticulum stress. J. Biol. Chem., 2004, 279(48), 49689-49693.
70. Wang, N.; Zhang, D.; Mao, X.; Zou, F.; Jin, H.; Ouyang, J. Astragalus polysaccharides decreased the expression of PTP1B through relieving ER stress induced activation of ATF6 in a rat model of type 2 diabetes. Mol. Cell. Endocrinol., 2009, 307(1-2), 89-98.
71. Parvaneh, L.; Meshkani, R.; Bakhtiyari, S.; Mohammadtaghvaie, N.; Gorganifiruzjaee, S.; Taheripak, G.; Golestani, A.; Foruzandeh, M.; Larijani, B.; Taghikhani, M. Palmitate and inflammatory state additively induce the expression of PTP1B in muscle cells. Biochem. Biophys. Res. Commun., 2010, 396(2), 467-471.
72. Panzhinskiy, E.; Hua, Y.; Culver, B.; Ren, J.; Nair, S. Endoplasmic reticulum stress upregulates protein tyrosine phosphatase 1B and impairs glucose uptake in cultured myotubes. Diabetologia, 2012, 56(3), 598-607.
73. Zhang, S.; Zhang, Z.-Y. PTP1B as a drug target: Recent developments in PTP1B inhibitor discovery. Drug Discov. Today, 2007, 12(9-10), 373-381.
74. Barr, A.J. Protein tyrosine phosphatases as drug targets: Strategies and challenges of inhibitor development. Future Med. Chem., 2010, 2(10), 1563-1576.
75. Montalibet, J.; Kennedy, B.P. Therapeutic strategies for targeting PTP1B in diabetes. Drug Discovery Today: Ther. Strategies, 2005, 2(2), 129-135.
76. Bourdeau, A.; Dube, N.; Heinonen, K.M.; Theberge, J.-F.; Doody, K.M.; Tremblay, M.L. TC-PTP-deficient bone marrow stromal cells fail to support normal B lymphopoiesis due to abnormal secretion of interferon-g. Blood, 2007, 109(10), 4220-4228.
77. Bettaieb, A.; Liu, S.; Xi, Y.; Nagata, N.; Matsuo, K.; Matsuo, I.; Chahed, S.; Bakke, J.; Keilhack, H.; Tiganis, T.; Haj, F.G. Differential regulation of endoplasmic reticulum stress by protein tyrosine phosphatase 1B and T cell protein tyrosine phosphatase. J. Biol. Chem., 2011, 286(11), 9225-9235.
78. White, M.F. Insulin signaling in health and disease. Science, 2003, 302 (5651), 1710-1711.
79. Zhang, Z.-Y. Protein tyrosine phosphatases: Structure and function, substrate specificity, and inhibitor development. Annu. Rev. Pharmacol. Toxicol., 2002, 42(1), 209-234.
80. Erbe, D.V.; Wang, S.; Zhang, Y.-L.; Harding, K.; Kung, L.; Tam, M.; Stolz, L.; Xing, Y.; Furey, S.; Qadri, A.; Klaman, L.D.; Tobin, J.F. Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms. Mol. Pharmacol., 2005, 67(1), 69-77.
81. Zhao, H. Lead optimization in the nondrug-like space. Drug Discov. Today, 2011, 16(3-4), 158-163.
82. Basu, S.; Prasad, U.V.; Barawkar, D.A.; De, S.; Palle, V.P.; Menon, S.; Patel, M.; Thorat, S.; Singh, U.P.; Sarma, K.D.; Waman, Y.; Niranjan, S.; Pathade, V.; Gaur, A.; Reddy, S.; Ansari, S. Discovery of novel and potent heterocyclic carboxylic acid derivatives as protein tyrosine phosphatase 1B inhibitors. Bioorg. Med. Chem. Lett., 2012, 22(8), 2843-2849.
83. Ottana, R.; Maccari, R.; Amuso, S.; Wolber, G.; Schuster, D.; Herdlinger, S.; Manao, G.; Camici, G.; Paoli, P., New 4-[(5-arylidene-2-arylimino-4-oxo-3- thiazolidinyl)methyl]benzoic acids active as protein tyrosine phosphatase inhibitors endowed with insulinomimetic effect on mouse C2C12 skeletal muscle cells. Eur. J. Med. Chem., 2012, 50, 332-343.
84. Joshi, P.; Deora, G.; Rathore, V.; Tanwar, O.; Rawat, A.; Srivastava, A.K.; Jain, D. Identification of ZINC02765569: A potent inhibitor of PTP1B by vHTS. Med. Chem. Res., 2013, 22(1), 28-34.
85. Joshi, P.; Deora, G.; Rathore, V.; Rawat, A.; Srivastava, A.K.; Jain, D. Molecular modeling and synthesis of ZINC02765569 derivatives as protein tyrosine phosphatase 1B inhibitors: Lead optimization study. Med. Chem. Res., 2013, 22(4), 1618-1623.
86. Kolb, H.C.; Finn, M.G.; Sharpless, K.B. Click chemistry: Diverse chemical function from a few good reactions. Angew. Chem., Int. Ed., 2001, 40(11), 2004-2021.
87. Xie, J.; Seto, C.T. A two stage click-based library of protein tyrosine phosphatase inhibitors. Bioorg. Med. Chem., 2007, 15(1), 458-473.
88. Bertozzi, C.R.; Kiessling; Laura, L. Chemical glycobiology. Science, 2001, 291(5512), 2357-2364.
89. Meutermans, W.; Le, G.T.; Becker, B. Carbohydrates as scaffolds in drug discovery. ChemMedChem, 2006, 1(11), 1164-1194.
90. Yang, J.-W.; He, X.-P.; Li, C.; Gao, L.-X.; Sheng, L.; Xie, J.; Shi, X.-X.; Tang, Y.; Li, J.; Chen, G.-R. A unique and rapid approach toward the efficient development of novel protein tyrosine phosphatase (PTP) inhibitors based on 'clicked' pseudo-glycopeptides. Bioorg. Med. Chem. Lett., 2011, 21(4), 1092-1096.
91. Song, Z.; He, X.-P.; Li, C.; Gao, L.-X.; Wang, Z.-X.; Tang, Y.; Xie, J.; Li, J.; Chen, G.-R. Preparation of triazole-linked glycosylated a-ketocarboxylic acid derivatives as new PTP1B inhibitors. Carbohydr. Res., 2011, 346(1), 140-145.
92. Song, Z.; He, X.-P.; Jin, X.-P.; Gao, L.-X.; Sheng, L.; Zhou, Y.-B.; Li, J.; Chen, G.-R. 'Click' to bidentate bis-triazolyl sugar derivatives with promising biological and optical features. Tetrahedron Lett., 2011, 52(8), 894-898.
93. He, X.-P.; Deng, Q.; Gao, L.-X.; Li, C.; Zhang, W.; Zhou, Y.-B.; Tang, Y.; Shi, X.-X.; Xie, J.; Li, J.; Chen, G.-R.; Chen, K. Facile fabrication of promising protein tyrosine phosphatase (PTP) inhibitor entities based on 'clicked' serine/threonine-monosaccharide hybrids. Bioorg. Med. Chem., 2011, 19 (13), 3892-3900.
94. Li, C.; He, X.-P.; Zhang, Y.-J.; Li, Z.; Gao, L.-X.; Shi, X.-X.; Xie, J.; Li, J.; Chen, G.-R.; Tang, Y. Click to a focused library of benzyl 6-triazolo(hydroxy)benzoic glucosides: Novel construction of PTP1B inhibitors on a sugar scaffold. Eur. J. Med. Chem., 2011, 46(9), 4212-4218.
95. Luo, L.; He, X.-P.; Shen, Q.; Li, J.-Y.; Shi, X.-X.; Xie, J.; Li, J.; Chen, G.-R. Synthesis of (glycopyranosyl-triazolyl)-purines and their Inhibitory activities against protein tyrosine phosphatase 1B (PTP1B). Chem. Biodiversity, 2011, 8(11), 2035-2044.
96. Yuan, C.; Lu, L.; Wu, Y.; Liu, Z.; Guo, M.; Xing, S.; Fu, X.; Zhu, M. Synthesis, characterization, and protein tyrosine phosphatases inhibition activities of oxovanadium(IV) complexes with Schiff base and polypyridyl derivatives. J. Inorg. Biochem., 2010, 104(9), 978-986.
97. Wang, Q.; Zhu, M.; Zhu, R.; Lu, L.; Yuan, C.; Xing, S.; Fu, X.; Mei, Y.; Hang, Q., Exploration of a-aminophosphonate Nderivatives as novel, potent and selective inhibitors of protein tyrosine phosphatases. Eur. J. Med. Chem., 2012, 49, 354-364.
98. Mak, L.H.; Knott, J.; Scott, K.A.; Scott, C.; Whyte, G.F.; Ye, Y.; Mann, D.J.; Ces, O.; Stivers, J.; Woscholski, R. Arylstibonic acids are potent and isoform-selective inhibitors of Cdc25a and Cdc25b phosphatases. Bioorg. Med. Chem., 2012, 20(14), 4371-4376.
99. Xie, J.; Tian, J.; Su, L.; Huang, M.; Zhu, X.; Ye, F.; Wan, Y. Pyrrolo[ 2,3-c]azepine derivatives: A new class of potent protein tyrosine phosphatase 1B inhibitors. Bioorg. Med. Chem. Lett., 2011, 21(14), 4306-4309.
100. Gupta, S.; Pandey, G.; Rahuja, N.; Srivastava, A.K.; Saxena, A.K. Design, synthesis and docking studies on phenoxy-3-piperazin-1-yl-propan-2-ol derivatives as protein tyrosine phosphatase 1B inhibitors. Bioorg. Med. Chem. Lett., 2010, 20(19), 5732-5734.
101. Dai, H.-l.; Gao, L.-x.; Yang, Y.; Li, J.-y.; Cheng, J.-g.; Li, J.; Wen, R.; Peng, Y.-q.; Zheng, J.-b. Discovery of di-indolinone as a novel scaffold for protein tyrosine phosphatase 1B inhibitors. Bioorg. Med. Chem. Lett., 2012, 22(24), 7440-7443.
102. Park, H.; Bhattarai, B.R.; Ham, S.W.; Cho, H. Structure-based virtual screening approach to identify novel classes of PTP1B inhibitors. Eur. J. Med. Chem., 2009, 44(8), 3280-3284.
103. Kumar, R.; Shinde, R.N.; Ajay, D.; Sobhia, M.E. Probing interaction requirements in PTP1B inhibitors: A comparative molecular dynamics study. J. Chem. Inf. Model., 2010, 50(6), 1147-1158.
104. He, Y.; Zeng, L.-F.; Yu, Z.-H.; He, R.; Liu, S.; Zhang, Z.-Y. Bicyclic benzofuran and indole-based salicylic acids as protein tyrosine phosphatase inhibitors. Bioorg. Med. Chem., 2012, 20(6), 1940-1946.
105. Patel, D.; Jain, M.; Shah, S.R.; Bahekar, R.; Jadav, P.; Joharapurkar, A.; Dhanesha, N.; Shaikh, M.; Sairam, K.V.V.M.; Kapadnis, P. Discovery of potent, selective and orally bioavailable triarylsulfonamide based PTP1B inhibitors. Bioorg. Med. Chem. Lett., 2012, 22(2), 1111-1117.
106. Patel, D.; Jain, M.; Shah, S.R.; Bahekar, R.; Jadav, P.; Darji, B.; Siriki, Y.; Bandyopadhyay, D.; Joharapurkar, A.; Kshirsagar, S.; Patel, H.; Shaikh, M.; Sairam, K.V.V.M.; Patel, P. Discovery of orally active, potent, and selective benzotriazole-based PTP1B inhibitors. ChemMedChem, 2011, 6(6), 1011-1016.
107. Lakshminarayana, N.; Rajendra Prasad, Y.; Gharat, L.; Thomas, A.; Ravikumar, P.; Narayanan, S.; Srinivasan, C.V.; Gopalan, B. Synthesis and evaluation of some novel isochroman carboxylic acid derivatives as potential anti-diabetic agents. Eur. J. Med. Chem., 2009, 44(8), 3147-3157.
108. Ye, D.; Zhang, Y.; Wang, F.; Zheng, M.; Zhang, X.; Luo, X.; Shen, X.; Jiang, H.; Liu, H. Novel thiophene derivatives as PTP1B inhibitors with selectivity and cellular activity. Bioorg. Med. Chem., 2010, 18(5), 1773-1782.
109. Lakshminarayana, N.; Prasad, Y.R.; Gharat, L.; Thomas, A.; Narayanan, S.; Raghuram, A.; Srinivasan, C.V.; Gopalan, B. Synthesis and evaluation of some novel dibenzo[b,d]furan carboxylic acids as potential anti-diabetic agents. Eur. J. Med. Chem., 2010, 45(9), 3709-3718.
110. Ma, Y.-m.; Tao, R.-y.; Liu, Q.; Li, J.; Tian, J.-y.; Zhang, X.-l.; Xiao, Z.-y.; Ye, F. PTP1B inhibitor improves both insulin resistance and lipid abnormalities in vivo and in vitro. Mol. Cell. Biochem., 2011, 357(1), 65-72.
111. Cheung, A.W.-H.; Banner, B.; Bose, J.; Kim, K.; Li, S.; Marcopulos, N.; Orzechowski, L.; Sergi, J.A.; Thakkar, K.C.; Wang, B.-B.; Yun, W.; Zwingelstein, C.; Berthel, S.; Olivier, A.R. 7-Phenylpyrido[ 2,3-d]pyrimidine-2,4-diamines: Novel and highly selective protein tyrosine phosphatase 1B inhibitors. Bioorg. Med. Chem. Lett., 2012, 22(24), 7518-7522.
112. Navarrete-Vazquez, G.; Ramírez-Martínez, M.; Estrada-Soto, S.; Nava-Zuazo, C.; Paoli, P.; Camici, G.; Escalante-García, J.; Medina-Franco, J.L.; López-Vallejo, F.; Ortiz-Andrade, R., Synthesis, in vitro and in silico screening of ethyl 2-(6-substituted benzo[d]thiazol-2- ylamino)-2-oxoacetates as protein-tyrosine phosphatase 1B inhibitors. Eur. J. Med. Chem., 2012, 53, 346-355.
113. Srinivas, N. The rationality for using prodrug approach in drug discovery programs for new xenobiotics: Opportunities and challenges. Eur. J. Drug Metab. Pharmacokinet., 2011, 36(2), 49-59.
114. Erbe, D.V.; Klaman, L.D.; Wilson, D.P.; Wan, Z.K.; Kirincich, S.J.; Will, S.; Xu, X.; Kung, L.; Wang, S.; Tam, S.; Lee, J.; Tobin, J.F. Prodrug delivery of novel PTP1B inhibitors to enhance insulin signalling. Diabetes Obes. Metab., 2009, 11(6), 579-588.
115. Arrendale, A.; Kim, K.; Choi, J.; Li, W.; Geahlen, R.; Borch, R. Synthesis of a phosphoserine mimetic prodrug with potent 14-3-3 protein inhibitory activity. Chem. Biol., 2012, 19(6), 764-771.
116. Baskaran, S.K.; Goswami, N.; Selvaraj, S.; Muthusamy, V.S.; Lakshmi, B.S. Molecular dynamics approach to probe the allosteric inhibition of PTP1B by chlorogenic and cichoric acid. J. Chem. Inf. Model., 2012, 52(8), 2004-2012.
117. Lantz, K.A.; Hart, S.G.E.; Planey, S.L.; Roitman, M.F.; Ruiz-White, I.A.; Wolfe, H.R.; McLane, M.P. Inhibition of PTP1B by trodusquemine (MSI-1436) causes fat-specific weight loss in dietinduced obese mice. Obesity, 2010, 18(8), 1516-1523.
118. Wasser, S. Current findings, future trends, and unsolved problems in studies of medicinal mushrooms. Appl. Microbiol. Biotechnol., 2011, 89(5), 1323-1332.
119. Teng, B.-S.; Wang, C.-D.; Yang, H.-J.; Wu, J.-S.; Zhang, D.; Zheng, M.; Fan, Z.-H.; Pan, D.; Zhou, P. A protein tyrosine phosphatase 1B activity inhibitor from the fruiting bodies of Ganoderma lucidum (Fr.) Karst and its hypoglycemic potency on streptozotocin-induced type 2 diabetic mice. J. Agric. Food Chem., 2011, 59(12), 6492-6500.
120. Wang, C.-D.; Teng, B.-S.; He, Y.-M.; Wu, J.-S.; Pan, D.; Pan, L.-F.; Zhang, D.; Fan, Z.-H.; Yang, H.-J.; Zhou, P. Effect of a novel proteoglycan PTP1B inhibitor from Ganoderma lucidum on the amelioration of hyperglycaemia and dyslipidaemia in db/db mice. Br. J. Nutr., 2012, 108(11), 2014-2025.
121. Baumgartner, R.R.; Steinmann, D.; Heiss, E.H.; Atanasov, A.G.; Ganzera, M.; Stuppner, H.; Dirsch, V.M. Bioactivity-guided isolation of 1,2,3,4,6-penta-O-galloyl-D-glucopyranose from Paeonia lactiflora roots as a PTP1B inhibitor. J. Nat. Prod., 2010, 73(10), 1742-1742.
122. Li, S.; Li, W.; Wang, Y.; Asada, Y.; Koike, K. Prenylflavonoids from Glycyrrhiza uralensis and their protein tyrosine phosphatase-1B inhibitory activities. Bioorg. Med. Chem. Lett., 2010, 20(18), 5398-5401.
123. Zhang, J.; Shen, Q.; Lu, J.-C.; Li, J.-Y.; Liu, W.-Y.; Yang, J.-J.; Li, J.; Xiao, K. Phenolic compounds from the leaves of Cyclocarya paliurus (Batal.) Ijinskaja and their inhibitory activity against PTP1B. Food Chem., 2010, 119(4), 1491-1496.
124. Wang, J.-R.; Shen, Q.; Fang, L.; Peng, S.-Y.; Yang, Y.-M.; Li, J.; Liu, H.-L.; Guo, Y.-W. Structural and stereochemical studies of five new pregnane steroids from the stem bark of Toona ciliata var. pubescens. Steroids, 2011, 76(6), 571-576.
125. Hoang, D.M.; Ngoc, T.M.; Dat, N.T.; Ha, D.T.; Kim, Y.H.; Luong, H.V.; Ahn, J.S.; Bae, K. Protein tyrosine phosphatase 1B inhibitors isolated from Morus bombycis. Bioorg. Med. Chem. Lett., 2009, 19(23), 6759-6761.
126. Heiss, E.H.; Baumgartner, L.; Schwaiger, S.; Heredia, R.J.; Atanasov, A.G.; Rollinger, J.M.; Stuppner, H.; Dirsch, V.M. Ratanhiaphenol III from Ratanhiae radix is a PTP1B inhibitor. Planta Med., 2012, 78(7), 678-681.
127. Li, Y.; Wang, T.-T.; Zhao, J.; Shi, X.; Hu, S.-C.; Gao, K. Norditerpenoids from Agathis macrophylla. Food Chem., 2012, 131(3), 972-976.
128. Nguyen, P.H.; Le, T.V.T.; Thuong, P.T.; Dao, T.T.; Ndinteh, D.T.; Mbafor, J.T.; Kang, K.W.; Oh, W.K. Cytotoxic and PTP1B inhibitory activities from Erythrina abyssinica. Bioorg. Med. Chem. Lett., 2009, 19(23), 6745-6749.
129. Dao, T.T.; Nguyen, P.H.; Thuong, P.T.; Kang, K.W.; Na, M.; Ndinteh, D.T.; Mbafor, J.T.; Oh, W.K. Pterocarpans with inhibitory effects on protein tyrosine phosphatase 1B from Erythrina lysistemon Hutch. Phytochemistry, 2009, 70(17-18), 2053-2057.
130. Nguyen, P.H.; Dao, T.T.; Kim, J.; Phong, D.T.; Ndinteh, D.T.; Mbafor, J.T.; Oh, W.K. New 5-deoxyflavonoids and their inhibitory effects on protein tyrosine phosphatase 1B (PTP1B) activity. Bioorg. Med. Chem., 2011, 19(11), 3378-3383.
131. Nguyen, P.H.; Sharma, G.; Dao, T.T.; Uddin, M.N.; Kang, K.W.; Ndinteh, D.T.; Mbafor, J.T.; Oh, W.K. New prenylated isoflavonoids as protein tyrosine phosphatase 1B (PTP1B) inhibitors from Erythrina addisoniae. Bioorg. Med. Chem., 2012, 20(21), 6459-6464.
132. Choi, Y.H.; Zhou, W.; Oh, J.; Choe, S.; Kim, D.W.; Lee, S.H.; Na, M. Rhododendric acid A, a new ursane-type PTP1B inhibitor from the endangered plant Rhododendron brachycarpum G.Don. Bioorg. Med. Chem. Lett., 2012, 22(19), 6116-6119.
133. Ma, J.; Li, Z.; Xing, S.; Ho, W.-T.T.; Fu, X.; Zhao, Z.J. Tea contains potent inhibitors of tyrosine phosphatase PTP1B. Biochem. Biophys. Res. Commun., 2011, 407(1), 98-102.
134. Li, Y.; Zhang, Y.; Shen, X.; Guo, Y.-W. A novel sesquiterpene quinone from Hainan sponge Dysidea villosa. Bioorg. Med. Chem. Lett., 2009, 19(2), 390-392.
135. Liang, L.-F.; Wang, X.-J.; Zhang, H.-Y.; Liu, H.-L.; Li, J.; Lan, L.-F.; Zhang, W.; Guo, Y.-W. Bioactive polyhydroxylated steroids from the Hainan soft coral Sinularia depressa Tixier-Durivault. Bioorg. Med. Chem. Lett., 2013, 23(5), 1334-1337.
136. Yamazaki, H.; Sumilat, D.A.; Kanno, S.I.; Ukai, K.; Rotinsulu, H.; Wewengkang, D.S.; Ishikawa, M.; Mangindaan, R.E.; Namikoshi, M. A polybromodiphenyl ether from an Indonesian marine sponge Lamellodysidea herbacea and its chemical derivatives inhibit protein tyrosine phosphatase 1B, an important target for diabetes treatment. J. Nat. Med. [Online], 2012. http://link.springer.com/article/10.1007%2Fs11418-012-0735-y (Accessed February 14, 2013).
137. Suhitha, S.; Gunasekaran, K.; Velmurugan, D. Structure based design of compounds from natural sources for diabetes and inflammation. Bioinformation, 2012, 8(23), 1125-1131.
138. He, H.-B.; Gao, L.-X.; Deng, Q.-F.; Ma, W.-P.; Tang, C.-L.; Qiu, W.-W.; Tang, J.; Li, J.-Y.; Li, J.; Yang, F. Synthesis and biological evaluation of 4,4-dimethyl lithocholic acid derivatives as novel inhibitors of protein tyrosine phosphatase 1B. Bioorg. Med. Chem. Lett., 2012, 22(23), 7237-7242.
139. Huang, F.-x.; Yang, W.-z.; Ye, F.; Tian, J.-y.; Hu, H.-b.; Feng, L.-m.; Guo, D.-a.; Ye, M. Microbial transformation of ursolic acid by Syncephalastrum racemosum (Cohn) Schroter AS 3.264. Phytochemistry, 2012, 82(0), 56-60.
140. Hung, T.M.; Hoang, D.M.; Kim, J.C.; Jang, H.-S.; Ahn, J.S.; Min, B.-S. Protein tyrosine phosphatase 1B inhibitory by dammaranes from Vietnamese Giao-Co-Lam tea. J. Ethnopharmacol., 2009, 124(2), 240-245.
141. Xu, J.-Q.; Shen, Q.; Li, J.; Hu, L.-H. Dammaranes from Gynostemma pentaphyllum and synthesis of their derivatives as inhibitors of protein tyrosine phosphatase 1B. Bioorg. Med. Chem., 2010, 18(11), 3934-3939.
142. Yoon, G.; Lee, W.; Kim, S.-N.; Cheon, S.H. Inhibitory effect of chalcones and their derivatives from Glycyrrhiza inflata on protein tyrosine phosphatase 1B. Bioorg. Med. Chem. Lett., 2009, 19(17), 5155-5157.
143. Liu, Z.; Lee, W.; Kim, S.-N.; Yoon, G.; Cheon, S.H. Design, synthesis, and evaluation of bromo-retrochalcone derivatives as protein tyrosine phosphatase 1B inhibitors. Bioorg. Med. Chem. Lett., 2011, 21(12), 3755-3758.
144. Shi, D.; Li, J.; Jiang, B.; Guo, S.; Su, H.; Wang, T. Bromophenols as inhibitors of protein tyrosine phosphatase 1B with antidiabetic properties. Bioorg. Med. Chem. Lett., 2012, 22(8), 2827-2832.
145. Jiang, B.; Shi, D.; Cui, Y.; Guo, S. Design, synthesis, and biological evaluation of bromophenol derivatives as protein tyrosine phosphatase 1B inhibitors. Arch. Pharm. (Weinheim). 2012, 345(6), 444-453.
146. Qiu, W.-W.; Shen, Q.; Yang, F.; Wang, B.; Zou, H.; Li, J.-Y.; Li, J.; Tang, J. Synthesis and biological evaluation of heterocyclic ring-substituted maslinic acid derivatives as novel inhibitors of protein tyrosine phosphatase 1B. Bioorg. Med. Chem. Lett., 2009, 19(23), 6618-6622.